Viatris (VTRS) vs Zoetis (ZTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Viatris (VTRS) has outperformed Zoetis (ZTS) over the past year, gaining 74.9% versus a loss of 49.1%. Over five years, VTRS leads with a +29.6% price change compared with -63.9% for ZTS. Zoetis is the larger company by market cap ($30.73 billion vs $20.26 billion), about 1.5 times the size.
On valuation, Viatris trades at a lower forward P/E (6.6x vs 11.4x for Zoetis). Zoetis offers the higher dividend yield (2.77% vs 2.72%). Zoetis converts more of its revenue into profit, with a net margin of 28.2% versus -24.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VTRS | ZTS |
|---|---|---|
| Share price | $17.64 | $74.36 |
| Market cap | $20.26B | $30.73B |
| 1-day change | +1.15% | +1.74% |
| YTD return | +40.08% | -41.92% |
| 1-year return | +74.92% | -49.07% |
| 5-year return | +29.57% | -63.86% |
| P/E ratio (TTM) | — | 12.23 |
| Forward P/E | 6.60 | 11.36 |
| EPS (TTM) | $-0.36 | $6.08 |
| Dividend yield | 2.72% | 2.77% |
| Annual dividend | $0.48 | $2.06 |
| Revenue (latest FY) | $14.30B | $9.47B |
| Revenue growth (YoY) | -2.98% | +2.28% |
| Net income (latest FY) | $-3.51B | $2.67B |
| Gross margin | 35.06% | 71.84% |
| Operating margin | -18.62% | — |
| Net margin | -24.58% | 28.23% |
| 52-week high | $18.43 | $148.30 |
| 52-week low | $9.69 | $68.77 |
| Distance from 52-week high | -4.29% | -49.86% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +11.68% | +29.11% |
| Average volume | 9.25M | 5.46M |
| Shares outstanding | 1.15B | 413.22M |
| Employees | 30,000 | 14,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTRS has outperformed ZTS by 124.0 percentage points over the past year.
- Zoetis is more profitable, keeping 28.2 cents of every revenue dollar as net income versus -24.6 cents for Viatris.
- Zoetis grew revenue faster in its latest fiscal year (+2.28% vs -2.98%).
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees
About Zoetis
ZTS stock →Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 14,500 employees
VTRS vs ZTS FAQ
Which is bigger, Viatris or Zoetis?
Zoetis (ZTS) is larger, with a market capitalization of $30.73B compared with $20.26B for Viatris (VTRS).
Which stock has performed better over the past year, VTRS or ZTS?
VTRS returned +74.92% over the past 12 months, compared with -49.07% for ZTS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Viatris or Zoetis?
Zoetis has the higher yield at 2.77%, compared with 2.72% for Viatris.
Are Viatris and Zoetis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.